Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

References

• Mountain CE Revisions in the international staging system for staging lung cancer. Chest 111, 1710–1717 (1997).
   Google Scholar
• Mountain CF, Dressler CM. Regional lymph node classification for lung cancer staging. Chest111, 1718–1723 (1997).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BE Merl 1311, 899 (1995).
   Google Scholar
• •Important meta-analysis demonstrating the benefits of what currently would be considered suboptimal chemotherapy for advanced NSCLC.
   Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak S et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A cooperative group study. J: Clin. 0=1 10, 1066–1073 (1992).
   Google Scholar
• Le Chavalier T, Brisgand D, Douillard JY et al Randomized study of vinorelbine and cisplatin versurvindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. Glitz Oncol 12,360–367 (1994).
   PubMedGoogle Scholar
• Wozniak AJ, Crowley JJ, Balcerzak S et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A cooperative group study. J: Gun. 0=1 10, 1066–1073 (1992).
   Google Scholar
• Pisters KMW. Surgery and Chemotherapy. In: Lung Cancer (2nd Edition). Pass H et al. (Eds.), Lippincott, Williams and Wilkins, Philadelphia, USA 769–777 (2000).
   Google Scholar
• Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or Illa non-small cell lung cancer. N. Engl. Merl 343,1217–1222 (2000).
   PubMed Web of Science ®Google Scholar
• PORT Meta-Analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352,257–263 (1998).
   PubMedGoogle Scholar
• Kato H, Konaka C, Tsuboi M et al. A randomized Phase III study comparing ubenimex (Bestatin) versus placebo as postoperative adjuvant treatment in patients with stage I squamous cell lung cancer. Proc. Am. Soc. Clin. Oncol 20, 307a(#1225) (2001).
   Google Scholar
• Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer 29 (Suppl. 2), 168–171 (2000).
   Google Scholar
• Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage Illa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg. 55(6), 1365–1373 (1993).
   Google Scholar
• Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thorac. Surg. 53, 992–998 (1992).
   Google Scholar
• Roth JA, Fossella F, Komaki R et al. Randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage Illa non-small cell lung cancer. J: Natl Cancer Inst. 86,673–680 (1994).
   PubMed Web of Science ®Google Scholar
• Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl. I Merl 330,153–158 (1994).
   PubMed Web of Science ®Google Scholar
• •Prospective trial demonstrating benefit of preoperative chemotherapy. Limited by its early closure and possible imbalances in prognostic features.
   Google Scholar
• Pisters KMW, Ginsberg RJ, Giroux DJ et al Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. .1. Thorac. Catrliovasc. Surg. 119(3), 429–439 (2000).
   Google Scholar
• ••The BLOT trial. Basis for much of thecurrent controversy.
   Google Scholar
• Depierre A, Milleron B, Moro D et al. Phase III trial of neoadjuvant chemotherapy in resectable stage I (except T1N0), II, MA non-small cell lung cancer: The French experience. Proc. Arn. Soc. Clin. 0=1 18, 465a (Abstract 1747) (1999).
   Google Scholar
• Depierre A, Milleron B, Chevret S. French Phase IIII trial of preoperative chemotherapy in resectable stage I (except T1N0), II, Ma non-small cell lung cancer. Lung Cancer 29 (Suppl.), 91 (2000) .
   Google Scholar
• Scagliotti G. The CHEST trial of neoadjuvant gemcitabine/cisplatin vs. Surgery Alone in Stage I—II Patients. 7th IASCLC Workshop on the Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer, (2001).
   Google Scholar
• Schiller JH, Harrington D, Sandler A et al. A Randomized Phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19, 1 (Abstract 2) (2000).
   Google Scholar
• Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non—small-cell lung cancer. 1 Clin. Oncol 17, 12 (1999).
   Google Scholar
• Sandler A, Nemunaitis J, Dehnam C et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol 18, 454a (Abstract 1792) (1998).
   Google Scholar
• Crino L, Betti M, Gregorc V et al. Induction chemotherapy with gemcitabine and cisplatin in locally advanced stage III non-small Cell lung cancer. A Phase II Study. Proc. Arn. Soc. Clin. Oncol 18, 488a (Abstract 1883) (1999).
   Google Scholar
• Edelman MJ, Quam H, Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non- small cell lung cancer cell lines. Cancer Chemo. Pharm. (2001) (In Press).
   Google Scholar
• Carrato A, Garcia-Gómez J, Alberola V et al Carboplatin (CARBO) in Combination with Gemcitabine (GEM) in Advanced Non-Small Cell Lung Cancer (NSCLC). Comparison of Two Consecutive Phase II Trials Using Different Schedules. Proc. Arn. Soc. Clin. Oncol 18, 498a (Abstract 1922) (1999).
   Google Scholar
• Edelman MJ, Gandara DR, Lau D et al. Sequential chemotherapy in non-small cell lung cancer: carboplatin and gemcitabine followed by paclitaxel. Cancer 92 (2001) (In Press).
   Google Scholar
• Go RS, Adeji AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. j Clin. Oncol 17, 409–422 (1999).
   PubMed Web of Science ®Google Scholar
• Siegenthaler MP, Pisters KM, Merriman KW et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann. Moran Surg 71, 1105–1112 (2001).
   Google Scholar
• Breton JP, Westeel V, Milleron et al. Postoperative morbidity and mortality after neoadjuvant chemotherapy (NCT) for non small cell lung cancer (NSCLC) in the French Phase III trial. Proc. Arn. Soc. Clin. Oncol 20, 311a (#1239) (2001).
   Google Scholar
• Pisters KMW, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: Implications for the design of future non-small cell lung cancer combined modality trials. j Clin. Oncol 11, 1757–1762 (1993).
   PubMed Web of Science ®Google Scholar
• Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol 20, 307a (#1226) (2001).
   Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82, 241–250 (1999).
   PubMed Web of Science ®Google Scholar
• Bonomi P, Perez-Soler R, Chachoua A et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774 following platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Proceedings of the I I th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy New Orleans, USA (Abstract #386), (2000).
   Google Scholar
• Gaspar L, Gandara D, Chansky K et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic Stage Mb non-small cell lung cancer (NSCLC) (SWOG 9504): Patterns of failure and updated survival. Proc. Arn. Soc. Clin. Oncol 20, 315a (#1255) (2001).
   Google Scholar
• Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol 41(6), 497–504 (1998).
   Google Scholar
• Pisters K, Ginsberg R, Giroux D et al. Phase II bimodality lung oncology team (BLOT) trial of induction paclitaxel/ carboplatin (PC) in early stage non-small cell lung cancer (NSCLC): Effect of number of induction cycles, sites of relapse and survival. Pmc. Arn. Soc. Clin. Oncol 20, 323a (#1288) (2001).
   Google Scholar
• Furuse K, Hosoe S, Masuda N. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer treated with concurrent thoracic radiotherapy and chemotherapy. Proc. ASC019, 484a (#1893) (2000).
   Google Scholar